Trial Profile
A Phase 2, Interventional, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Glucagon RTU in Subjects Who Experience Hyperinsulinemic Hypoglycemia After Bariatric Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors XERIS Pharmaceuticals
- 22 May 2020 According to a XERIS Pharmaceuticals Media Release, the comapny expects end-of-phase 2 meeting with the FDA later this year to discuss a clinical path forward for this program.
- 22 May 2020 Results from the outpatient stage of this study (n=12) presented in the XERIS Pharmaceuticals Media Release.
- 20 May 2020 Status changed from active, no longer recruiting to completed.